Brokerages Set enGene Holdings Inc. (NASDAQ:ENGN) Target Price at $22.38

enGene Holdings Inc. (NASDAQ:ENGN) has been given an average rating of “Moderate Buy” by the ten research firms that are presently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have assigned a buy rating and one has issued a strong buy rating on the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $22.3750.

A number of equities analysts have commented on ENGN shares. HC Wainwright reissued a “buy” rating and set a $25.00 target price on shares of enGene in a report on Wednesday, December 3rd. UBS Group boosted their price target on enGene from $4.00 to $10.00 and gave the stock a “neutral” rating in a research report on Wednesday, November 12th. Citigroup restated a “market outperform” rating on shares of enGene in a report on Monday, January 5th. Raymond James Financial raised shares of enGene from an “outperform” rating to a “strong-buy” rating and set a $27.00 target price for the company in a report on Tuesday, November 11th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of enGene in a research report on Friday, January 9th.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Hudson Bay Capital Management LP purchased a new stake in shares of enGene in the third quarter valued at approximately $76,000. Millennium Management LLC boosted its stake in enGene by 57.3% during the third quarter. Millennium Management LLC now owns 20,502 shares of the company’s stock worth $140,000 after buying an additional 7,472 shares during the last quarter. Citadel Advisors LLC grew its holdings in enGene by 153.3% in the 3rd quarter. Citadel Advisors LLC now owns 58,370 shares of the company’s stock valued at $399,000 after buying an additional 35,327 shares in the last quarter. Braidwell LP purchased a new stake in enGene in the 3rd quarter valued at $15,479,000. Finally, Raymond James Financial Inc. increased its stake in shares of enGene by 383.6% in the 3rd quarter. Raymond James Financial Inc. now owns 10,000 shares of the company’s stock worth $68,000 after acquiring an additional 7,932 shares during the last quarter. 64.16% of the stock is owned by hedge funds and other institutional investors.

enGene Stock Performance

NASDAQ:ENGN opened at $9.10 on Friday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 6.30 and a current ratio of 6.30. The stock has a market capitalization of $609.56 million, a PE ratio of -3.97 and a beta of -0.29. enGene has a fifty-two week low of $2.65 and a fifty-two week high of $11.14. The company has a fifty day moving average of $8.22 and a two-hundred day moving average of $6.44.

enGene (NASDAQ:ENGN) last announced its earnings results on Monday, December 22nd. The company reported ($0.73) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.18). As a group, research analysts forecast that enGene will post -1.56 earnings per share for the current fiscal year.

About enGene

enGene, Inc is a clinical‐stage biopharmaceutical company focused on the development of gene‐based therapeutics for oncology. The company’s core technology is the EnGene Delivery Vehicle (EDV) platform, which employs nonliving, bacterially derived minicells to transport therapeutic payloads directly to tumor cells. By combining targeted delivery with potent payloads, enGene aims to improve the precision and efficacy of cancer treatments while reducing off‐target toxicity.

Through its EDV platform, enGene has advanced multiple therapeutic candidates into preclinical and clinical stages.